Difficult to know whether Davis was intimating that Acadia has acquired full rights to NNZ-2591 or if he simply failed to make clear that the NNZ-2591 rights acquired by Acadia are limited to Rett syndrome and Fragile-X.
Acadia, page-370
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.61 |
Change
-0.350(1.67%) |
Mkt cap ! $2.619B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.31 | $9.095M | 441.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 450 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 202 | 5 |
View Market Depth
| Last trade - 14.05pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.42 |
Change
-0.350 ( 3.06 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.32 | 130597 | ||
| Last updated 14.24pm 30/05/2024 ? | |||||
| NEU (ASX) Chart |